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Dendritic cells (DCs) are the most important member of the antigen presenting cells
group due to their ability to recognize antigen at the infection site and their high
specialized antigen internalization capacity. These cells have central role in connecting
the innate and adaptive immune responses against Trypanosoma cruzi, the causative
agent of Chagas disease. These first line defense cells modulate host immune response
depending on type, maturation level, cytokine milieu and DC receptor involved in the
interactions with T. cruzi, influencing the development of the disease clinic forms. Here,
we present a review of DCs–T. cruzi interactions both in human and murine models,
pointing out the parasite ability to manipulate DCs activity for the purpose of evading
innate immune response and assuring its own survival and persistence.
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INTRODUCTION
More than a century has passed since Carlos Chagas discovered the pathogen Trypanosoma cruzi
and the natural way of its transmission to humans and animals, and elucidated the corresponding
human disease it causes (Kropf and Sá, 2009). Chagas disease is also transmitted through blood
transfusions or organ transplants, vertically from mother to child through the placenta, and
through contaminated food (Andrade et al., 2014). This neglected disease affects predominantly
deprived people and induces social and economic impacts by decreasing patient’s productivity and
earning capacity (Hotez et al., 2007).
With 28,000 new cases per year and 8,000 newborns infected during gestation, Chagas disease
affects about 8 million people, beyond 65 million live in areas of exposure and are at risk of
contracting the disease (World Health Organization, 2015). Despite the efforts to reduce Chagas
disease and the number of infections over the last two decades, it is still endemic in Latin
America (Rassi et al., 2010; Strasen et al., 2013) and, as result of global migration, the number
of people infected with T. cruzi is increasing in North America, Europe, Japan and Oceania (non-
endemic areas) (Schmunis, 2007). Since Chagas disease crosses boundaries and spreads, it becomes
not only a burden for the endemic countries but a worldwide health concern (Andrade et al.,
2014).
Treatment of Chagas disease is one of the greatest therapeutic challenges in tropical medicine
since the only drugs approved for human treatment − Nifurtimox and Benznidazole − date
from the early 1970s and have carcinogenic properties conferred to nitrofuran and nitroimidazole,
their active chemical groups, respectively (Bern, 2011; Wilkinson et al., 2011). Nevertheless, both
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medicines share similar features: necessity of prolonged
administration, effectiveness related to the acute phase and
different susceptibility among T. cruzi strains (Bermudez et al.,
2015). Aditionally, Nifurtimox prescription has been abolished
in Brazil, Argentina, Uruguay, Chile and US due to its toxic
effects over central nervous system, genotoxicity, and reduced
efficacy (Wilkinson et al., 2011).
The natural disease progression consists of an acute phase
that can be followed by an asymptomatic indeterminate phase,
which represents most of the cases and, one-third of infected
population progress to the chronic phase that may lead to
death (Machado et al., 2013). Early clinical manifestations
include headache, fever, and cough, which are non-specific
signs; consequently most of infected individuals are neither
notified nor treated. Symptomatic chronic stage of the disease
usually occurs from 10 to 25 years after infection and typical
manifestations are mild to severe cardiomyopathy and/or dilated
digestive tract (megaoesophagus and megacolon) (Steverding,
2014). The mechanisms responsible for patient progression
from the indeterminate to the symptomatic chronic phase are
not completely understood, although the immunological events
initiated during the acute phase undoubtedly drive the organism
toward the development of a protective or deleterious immune
response (Andrade et al., 2014).
It is unanimity that during the acute phase, dendritic cells
(DC), along with macrophages, and natural killer (NK) cells,
guarantee the host first line of defense against the parasite
(Watanabe Costa et al., 2016). Guide by this context, our purpose
is to present a review about DC–T. cruzi interaction pointing out
the parasite ability to evade innate immune response to assure its
own survival and persistence.
Trypanosoma cruzi
Trypanosoma cruzi is an obligate intracellular protozoan of
the Kinetoplastea Class, characterized by the presence of
one flagellum and a single mitochondrion comprising the
kinetoplast, a specialized DNA-containing structure. The Order
Trypanosomatida comprises other parasites responsible for
severe diseases in humans and other species, for instance
Leishmania sp. (leishmaniasis), Trypanosoma brucei (African
trypanosomiasis), Phytomonas sp. (plant diseases), and Crithidia
sp. (arthropods diseases) (Stevens, 2008), that show adaptability
toward their hosts with numerous sophisticated immune evasion
strategies (D’Avila-Levy et al., 2015).
Trypanosoma cruzi strains present diversity in morphology,
infection capacity, cell surface predominant antigens and other
biological and biochemical features (de Lana et al., 2010). In
2009, the Second Satellite Meeting held in Buzios, Brazil suggested
six Discrete Typing Units (DTUs) for classifying the several
T. cruzi strains, named TcI to TcVI (Zingales et al., 2009).
A DTU is a population set that is more genetically related among
themselves than to any other population, showing common
genetic, immunological and molecular markers (Tibayrenc,
1998). These DTUs subsets have different distribution among
the American continent due to parasite adaptations to different
vectors and reservoirs (Zingales et al., 2012), and, although, some
characteristics are shared within the same DTU, differences in
many aspects can be found among strains. T. cruzi Colombian
and G strains, belonging to TcI group, are a clear example of this
intra-DTU diversity. Colombian strain, isolated from humans, is
highly infective (Ramírez et al., 2010), but no human infections
were reported from G strain, which was isolated from anal gland
secretions of an opossum (Deane et al., 1984). T. cruzi G strain
has gp35/50 as predominant surface glycoprotein that appears to
be related to its poor internalization by humans cells (Yoshida,
2006).
T. cruzi life cycle alternates between reduviid bug vectors and
mammal hosts. Domestic and wild animals like opossum, bats,
armadillo, and monkey may also act as reservoir host (Coura
et al., 2002). The parasite presents different forms during its life
cycle – epimastigotes remains in the insect gut; non-divinding
and infective metacyclic trypomastigotes (MT) find in the
insect feces and/or urine; bloodstream trypomastigotes that can
circulate in the mammalian blood and, finally, the intracellular,
proliferative and rounded amastigote form. A triatomine insect
picks up the parasite trypomastigote forms by feeding on the
blood of an infected mammal (Teixeira et al., 2009) and, once
inside the vector, those forms differentiate into epimastigotes and
multiply in midgut (Manchola et al., 2015). After migration to
the bug’s hindgut, epimastigotes attach to the waxy gut cuticle
by their flagella and differentiate into infectious MT, which will
be deposited along with feces/urine on the skin of the victim
(Muñoz-Saravia et al., 2012). The parasite penetrates the new
host through lesions caused by its bite or a variety of mucosal
membranes. MTs invade host cells entering a parasitophorous
vacuole (Romano et al., 2012), which fuses to lysosomes. Once
free in the cytoplasm, the parasite differentiates into amastigotes
that undergo binary fission multiplication and transform back
to trypomastigotes, which are released upon rupture of the
host cell membrane and infect neighboring cells or enter the
bloodstream (Stecconi-Silva et al., 2003; Tonelli et al., 2004).
Bloodstream trypomastigotes may begin another infection cycle
when they are taken in the blood feeding of the vector (Bern,
2015). Humans and animals can be infected orally through the
ingestion of food and drink contaminated by crushed infected
insect vectors or their feces (Nóbrega et al., 2009; Bastos et al.,
2010).
Immune evasion strategies developed by T. cruzi are essential
to the establishment of a long-life infection. Complement
inactivation, escape from phagolysosome, antibodies with no
T-cruzi specificity and delayed immune response are some
examples of those strategies (Reviewed by Nardy et al., 2015;
Cardoso et al., 2016). Another mechanism involved in parasite
persistence is the manipulation of DC functions, which impairs
an adequate host immune defense.
DENDRITIC CELLS
Dendritic cells are bone-marrow-derived cells that belong to the
antigen presenting cells (APC) group, being considered the most
important member due to their high capacity to recognize and
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internalize antigens at the infection site (Haniffa et al., 2009;
Collin et al., 2013). They link innate and adaptive immune
responses by capturing, processing and expressing antigens in
the cell surface membrane (Planelles et al., 2003; Steinman,
2007). Immature DCs have a wide range of innate receptors
that enables the recognition of pathogens via pattern recognition
receptors (PRRs), which activate DCs through signaling pathways
eliciting their maturation (Pearce and Everts, 2015). Toll-like
receptors (TLRs), abundant in APC, are one of the best-
characterized PPRs and efficiently detect pathogen-associated
molecular patterns (PAMPs) that are located on the cell surface
or in the lumen of endosomes. The presence of TLRs on the cell
surface or in the lumen of endosomes enables efficient pathogen
recognition and the development of an adequate innate immune
response; i.e., TLR2, located in DCs plasma membrane, senses
various components of pathogens and its stimulation induces
the production of various proinflammatory cytokines. TLR9,
located in DCs endolysosome, is involved in virus, bacteria,
protozoa nucleic acid recognition and its activation also leads
to the production of proinflammatory cytokines (Takeuchi and
Akira, 2010). After antigen recognition, DCs can travel along
the body from peripheral tissues to lymphoid organs/tissues
where they present the processed antigens through their major
histocompatibility complexes (MHC) to T cells (Lipscomb and
Masten, 2002). Maturation process comprises differentiation
from antigen-capturing specialized cells to presenting and
stimulating specialized cells. Mature DCs can be identified by
morphological aspects like cytoplasmic extensions and abundant
intracellular structures (lysosomes, endosomes, granules, etc.)
related to antigen processing and by modulation of molecular
markers such as up-regulation of CD83, of co-stimulatory
molecules like CD80 (or B7-1) and CD86 (or B7-2) and MHC
(O’Neill et al., 2004).
Dendritic cells present antigens to lymphocytes CD8+ and
CD4+ T by MHC class I and MHC class II, respectively
(Blum et al., 2013). For MHC class I molecules, these antigens
originate from intracellular sources; for MHC class II, from
exogenous sources. Some DCs have an atypical ability, called
cross-presentation that allows to load peptides from exogenous
antigens onto MHC class I molecules (Vyas et al., 2008; Neefjes
et al., 2011; Segura and Amigorena, 2015). MHC class I molecules
are expressed by all nucleated cells and their antigen presentation
pathway consists in a series of reactions: (1) intracellular proteins
are degraded by the proteasome; (2) the peptides are delivered
to the endoplasmic reticulum by the transporter associated
with antigen processing complex; (3) antigens are loaded onto
MHC class I molecules; (4) peptide–MHC class I complexes
are transported via the Golgi to cell surface for presentation to
CD8+ T cells (Vyas et al., 2008; Neefjes et al., 2011). Recently
it was demonstrated that infection of HeLa cells with T. cruzi
Y strain promotes a down-regulation of the immunoproteasome
subunits biosynthesis as well as the MHC class I molecule
expression, which could be considered a mechanism of parasite
persistence inside the cell (Camargo et al., 2014). Unlike MHC
class I expression, MHC class II are mainly expressed by APCs
such as DCs, macrophages and B cells (Vyas et al., 2008;
Neefjes et al., 2011). Extracellular antigens are taken up by
APCs and placed into the phagosome. This compartment fuses
with lysosomes to form phagolysosomes, where MHC class II
molecules interact with the antigens. Peptide-loaded MHC class
II molecules are then transported to the cell surface where
they engage antigen-specific CD4+ T cells (Vyas et al., 2008;
Neefjes et al., 2011). Curiously, MHC II molecules are in constant
recycle and degradation process in immature DCs, but mature
DCs exhibits a stable and prolonged antigen presentation (den
Haan et al., 2014). It is worth mentioning that DCs antigen
presentation is not enough for T lymphocytes activation and
proliferation. Co-stimulatory molecules expression and cytokine
production are also required and they are efficiently provided
by mature DCs (den Haan et al., 2014). Following activation
via TLRs, DCs may produce acute innate cytokines involved
in local and systemic responses such as IL-1β, IL-6, IL-8, IL-
12, and TNF-α (Verhasselt et al., 1997; Holdsworth and Can,
2015), however, DCs, under specific conditions, are also able to
produce IL-10 and TGF-β for directing a regulatory response
(Table 1).
Different DC subsets and maturation levels can produce
distinct kinds of cytokines or co-stimulatory molecules that can
lead either to an inflammatory or a regulatory response. Among
DC subsets, myeloid (mDC or classical DC), plasmocytoid
(pDC), Langerhans cells (LCs), and derived from monocytes
(monocyte DC) are some well-known examples. In murines,
mDCs are composed of two main groups: resident and migratory,
which are further divided into two subsets: Batf3-dependent and
IRF4-dependent DCs (Reviewed by Segura, 2016). mDC Batf3-
dependent/migratory expresses CD11c, Clec9A, XCR1, CD103,
and CD207; the resident one expresses CD11c, Clec9A, XCR1,
and CD8. On the other hand, mDC IRF4-dependent/resident
expresses CD11c, CD11b, CD172a; the same markers are found
in the migratory subsets along with CD206. The major markers
for pDC are CD11c, Ly6c, B220 and SiglecH. For monocyte
DC, they are CD11c, CD11b, CD64, FcεRI, CD206, CD14,
CD172a, and Ly6c (Reviewed by Segura, 2016). Finally, LCs
is a special DC population present in epidermis and other
stratified squamous epithelia, such as oral and genital mucous
membranes and bronchus. Despite of being associated with
these tissues, LCs may differentiate into migratory cells for
antigen presentation; their principal markers are CD11c, CD207,
EpCAM, and E-cadherin. Human mDCs classical markers are
CD1c+, Dectin 1 (CLEC 7A), and Dectin 2 (CLEC6A). Regarding
pDCs, CD303 (CLEC4C), CD304 (neuropilin), and CD123 (IL-
3R) are human usual markers. Monocyte DCs may express
CD14, CD209 (DC-SIGN), CD16, and CD1c (Reviewed by
Collin et al., 2013). Lewis and Reizis (2012) have proposed
the existence of two more kinds of DCs within these subsets:
“receptors”, cells more specialized in capturing antigens and
producing cytokines and “presenters”, cells that benefit from
these cytokines and travel to lymph nodes for presenting the
antigens. It represents another level of specialization among
DCs, stating their diversity and their capacity to guide polarity,
magnitude and specificity of immune responses (Lewis and
Reizis, 2012).
Some studies have demonstrated that acute and chronic
phases of Chagas disease require different polarizations of
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immune response: Th1 profile is protective in an acute state and
regulatory responses are important in preventing the chronic
phase (Andrade et al., 2014; Dutra et al., 2015). For this reason,
DCs are a key group of cells in Chagas disease: they could
modulate response depending on type, maturation level, cytokine
milieu and DC receptor involved, having a fundamental role
in the development of the disease clinic forms including the
undetermined stage.
DENDRITIC CELL−T. cruzi
INTERACTION: MURINE MODELS
Studies on acute Chagas disease in humans are limited due to
lack of unique symptoms that characterize this disease state.
Nonetheless, extending our knowledge about the acute phase
is important because immunological events that take place in
this stage have a great influence on the possible development
of the chronic phase (Andrade et al., 2014). In this context,
experimental murine infection may mimic the human disease,
giving us a similar view on what happens at the beginning of
T. cruzi infection.
Unlikely the habitual DCs response during an infection, the
expression of important surface molecules like MHC, CD80 or
CD86 can be reduced when DCs recognize T. cruzi antigens
in a strain dependent manner, limiting DC maturation and
antigen presenting capacity. During acute phase, splenic DCs
infected by T. cruzi Tehuantepec strain shows low expression of
CD86 molecules and are not able to migrate toward lymphoid
organs/tissues (Chaussabel et al., 2003). T. cruzi high virulent
RA strain (TcVI) induces bone-marrow DCs downregulation
of cytokine production and of endocytic capacity added to a
suppression of MHC class II, compared to non-infected cells
(Poncini et al., 2008). These data are in concordance with the
regulation studied by Alba Soto and coworkers, where they
also detected a diminished MHC II expression in infected
splenic DCs by the same T. cruzi strain. Additionally, they
showed that the DC manipulated behavior induced by RA
strain is not repeated for non-virulent K98 T. cruzi strain
(TcI) (Figure 1; Alba Soto et al., 2003). Another comparative
infection study, using mDCs, was performed using TcI (AQ1.7
and MUTUM) and TcII strains (1849 and 2369). The results
demonstrated that both T. cruzi DTUs may modulate DCs
to different extents and this modulation varied more between
strains than between DTUs themselves. In general, both DTUs
induced the production and expression of anti-inflammatory
molecules, such as IL-10, production and PD-L1 and TLR2
expression. Regarding TLR2 expression, it seems that T. cruzi
has molecules that bind this receptor promoting the production
of anti-inflammatory cytokines such as IL-10. Oppositely,
proinflammatory molecules did not present a pattern, varying
depending on the strain. Finally, they also demonstrated that
DC expression of differentiation and activation molecules was
not polarized, which suggests that each strain of T. cruzi has
possibly evolved specific evasion strategies (da Costa et al., 2014).
Interestingly, when two mice lineages were infected by high
virulent T. cruzi Y strain (TcII), the susceptible one showed
splenic DCs with reduced capacity of antigen presentation
and lower expression of CD40 and CD86 molecules compared
with resistant lineages (Planelles et al., 2003). It is well known
that the deficiency of co-stimulatory signals during cross-
presentation may reduce T cell stimulation or lead to an anergic
state (Boussiotis et al., 1996). Thus, it seems that impaired
function by DC maybe helps parasite to evade the host immune
system.
Cytokine production is another important aspect during
DCs−T. cruzi interaction, particularly the production of IL-12,
considered a protective molecule during the acute infection once
it drives a polarized Th1 adaptive response that enables the host
to adequately control parasite growth through IFN-γ (Andrade
et al., 2014). In concordance, DCs from T. cruzi-resistant mouse
lineages overexpressed IL-12 and TNF-α while the susceptible
lineages produced the Th2 cytokine IL-4 (Planelles et al., 2003).
IL-4 is known to mediate host susceptibility to T. cruzi but is
also required for preventing immune hyperactivity and organ
immunopathology (Abrahamsohn and Coffman, 1996; Laucella
et al., 1996). Terrazas et al. (2011) demonstrated the protective
role of IL-12 through T. cruzi Queretaro (TcI) strain infection
of MIF (macrophage migration inhibitory factor)-deficient mice.
MIF is a pleiotropic cytokine produced by multiple different cell
types, including DCs that modulates the expression of several
proinflammatory molecules (Cooke et al., 2009). It seems that
it favors DC maturation through IL-12 secretion and activation
of p38 MAPK protein, a kinase already known to be involved in
DC maturation. On the other hand, MIF-deficient mice showed
lower levels of IL-12 production and immature bone-marrow
DCs, leading to a susceptibility of T. cruzi Queretaro (TcI) strain
infection (Terrazas et al., 2011). The regulatory IL-10 cytokine
is also associated with host susceptibility during acute stage
of Chagas disease by limiting DCs induction of antimicrobial
effector mechanism such as suppressing DC trafficking to
draining lymph nodes (Corinti et al., 2001; Demangel et al., 2002;
Alba Soto et al., 2010). A single intravenous injection of IL-10-
deficient DCs that were pulsed with parasite antigens conferred
an effective control against a lethal challenge with T. cruzi RA
strain in mice. IL-10 deficient DCs were high Th1 cytokines
producers and inducers of antigen-specific T lymphocytes after
immunization (Alba Soto et al., 2010). On the other hand,
Poncini et al. (2010) have showed that interaction of DCs with
T. cruzi trypomastigotes was not able to activate the DCs, and
these cells became TGF-β and IL-10 producers and were not
efficient as lymphocyte stimulators, being classified as regulatory
DCs. Furthermore, mature DCs have the capacity to induce NK
cells activation and proliferation. NK cells play a significant role
in innate immune response and surveillance as a result of their
cytokine production and cytolysis of infected cells. Moreover, NK
cells secrete IFN-γ, TNF-α, and GM-CSF, which promote DC
maturation and activation of T-cell (Gerosa et al., 2002; Piccioli
et al., 2002). Batalla et al. (2013) used RA and K98 T. cruzi
strains to demonstrate the role of NK cells in regulating the
maturation level of DCs. During both infections, NK cell was
functionally activated and produced IFN-γ but also IL-10; NK
cells from mice infected with T. cruzi RA strain (high virulence)
exhibit reduced ability to lyse and fail to induce maturation
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FIGURE 1 | Possible scenarios after dendritic cells (DCs)−Trypanosoma cruzi interaction. DCs may maturate, up-regulating major histocompatibility
complexes (MHC) molecule expression and proinflammatory cytokine production, which may stimulate antigen-specific T lymphocyte activation and proliferation to
control parasitemia (magenta); or DCs may be manipulated and the resultant low MHC expression together with high regulatory cytokine production may lead to a
weak T cell activation, helping parasite establishment (blue). DC deviant behavior pathway could represent a potent immune evasion strategy of virulent T. cruzi
strains to successfully set host infection. On the other hand, less virulent T. cruzi strains lack DC modulation capacity, which enables host immune response and
parasite control.
of bone marrow-derived immature DCs. This unbalanced DC
population could difficult T cell stimulation for an adequate
response. Finally, that IL-10 production observed by NK cells
after infection with T. cruzi RA strain might lead to parasite
persistence but can also limit the induction of a vigorous
tissue-damaging T-cell response (Batalla et al., 2013). Cytokine
production may also be modulated by parasite initial inocula.
Three different inocula of T. cruzi Colombian strain were used
to infect mice, resulting in differential expression of IFN-γ, IL-
17, TNF-α, IL-4, and IL-23 by immune cells in heart infiltrates.
Curiously, the medium inoculum showed the less favorable host
response, which may indicate the existence of an ideal initial
inoculum to help parasite evade host immune response (Borges
et al., 2012).
It also has been shown the important role of TLRs in T. cruzi
recognition by first line of defense cells, including DCs. Campos
et al. (2004) demonstrated that T. cruzi employs a myeloid
differentiation factor 88 (MyD88)-, a key adaptor for most TLRs,
dependent pathway to elicit cytokine production by the host
cells. Intraperitoneal macrophages lacking MyD88 produced less
IFN-γ, IL-12, TNF-α and reactive nitrogen intermediates, they
also presented higher parasitemia and mortality (Campos et al.,
2004). The role of TLRs in the establishment of critical effector
mechanisms mediated by CD8+ T cells during T. cruzi infection
was also investigated (Oliveira et al., 2010). The analysis of
induction of IFN-γ and cytotoxic activity in vivo in TLR2-,
TLR4-, TLR9-, or MyD88-deficient mice during infection showed
that neither the absence of TLR2, TLR4, or TLR9 individually,
nor the ablation of all MyD88-mediated pathways affect the
development of cytotoxic and IFN-γ-producing CD8+ T cells.
Nonetheless, TLR4 deficient macrophages presented a reduced
production of TNF-α and nitric oxide (NO), pointing to an
important role of the TLR4 pathway and NO production to
the innate immune response against T. cruzi infection (Oliveira
et al., 2010). With regard specifically to DCs, infection with
T. cruzi parasites promotes recruitment of TLR9 to the DC
endolysosome compartment, promoting their interaction during
initial phagocytosis. Stimulatory motifs containing CpG islands
of T. cruzi CL Brener, particularly those formed by genes coding
for mucin like proteins, also led TLR9 into lysosomes of bone-
marrow DCs and the induction of IL-12 as well as IFN-γ synthesis
(Bartholomeu et al., 2008). Such potent proinflammatory activity
and, consequently, control of parasite replication could lead
to host resistance to infection or avoiding host lethality and
maintenance of parasite life cycle long-term parasite persistence.
The second hypothesis suggests another adaptation of T. cruzi
to the host cell-mediated immunity (Bartholomeu et al., 2008).
Gravina et al. (2013) stated that DC population constitutes
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the main source of IL-12/IL-23p40 production in a TLR9-
dependent manner in T. cruzi Y strain infection. Moreover,
when DCs were unable to produce IL-12/IL-23p40, macrophages
recovered their capacity to respond to TLR9 agonist, which
may represent a compensatory response. Therefore, modulation
of TLR9 is important to control the inflammatory response
in the different cell populations but TLR9 acts fundamentally
on DC inflammatory activity in T. cruzi infection (Gravina
et al., 2013). Synergy among TLRs in parasite infected DC has
also been studied. When MyD88/TRIF (Toll/IL-1R domain-
containing adaptor-inducing IFN-β) deficient mice (i.e., with
no functional activation of TLRs) were infected with T. cruzi
Tulahuen strain (TcVI), parasite clearance was impaired mainly
by absence of IFN-β production (Koga et al., 2006). In the same
work, it was proposed that proinflammatory cytokine production
is a MyD88-dependent induction and the expression of IFN-β is
a TRIF-dependent. In any case, both TLR adaptors contribute to
innate immune responses against T. cruzi infection (Koga et al.,
2006). UNC93B1, a protein that interacts with TLR3, TLR7, and
TLR9, seems to play an essential role in host protection against
T. cruzi infection (Caetano et al., 2011). UNC93B1 mice deficient
were more susceptible to T. cruzi infection and produced lower
concentration of IL-12p40 and IFN-γ. Such susceptibility was
also achieved during TLR3/TLR7/TLR9-deficient mice T. cruzi
infection, showing that nucleic acid-sensing TLRs are critical
determinants of host resistance to primary infection with T. cruzi
(Caetano et al., 2011).
Other receptors also have been proposed to play an important
role during the acute phase of Chagas disease. G-protein-coupled
bradykinin (BK) B2 receptors (B2R)-deficient mice were more
susceptible to T. cruzi Dm28c strain (TcI) infection than WT
animals (Monteiro et al., 2007). B2Rs recognize T. cruzi released
kinins, mediators related to bradykinin that activate immature
DCs (Monteiro et al., 2006). Splenic DCs without B2R receptor
do not produce IL-12, appointing a critical role for the kinin
signaling pathway in the development of type-1 effector T cells
(Monteiro et al., 2007). In a recent study, the same group
demonstrated that blockage of B2R along with C5a receptor
resulted in splenic DCs unable to produce IL-12p40/70 and
IFN-γ (Schmitz et al., 2014). C5a is an anaphylatoxin derived
from proteolysis of C5 complex of complement system, whose
biological function is to activate cells from myeloid lineage
(Klos et al., 2009). Yet, they showed that, as for kinins, C5a
molecules seems to be produced through T. cruzi cruzipain
activity during infection and can promote DC activation and
a Th1 protective response (Schmitz et al., 2014). Galectins, a
lectin receptor, can also act as pathogen recognition receptors
and as modulators of innate and adaptive response (Vasta,
2009). It has been shown that those receptors are widely
expressed in B cell, macrophages and DCs during T. cruzi
infection (Vray et al., 2004; Zúñiga et al., 2001a,b). Concerning
DCs, Galectin-1 seems to be a negative immune regulator
that limits the host protective response by driving tolerogenic
circuits in DCs. Those tolerogenic DCs induce regulatory T
cells activation, which would favor parasite persistence in host
tissues or limit collateral tissue damage through suppression of
inflammatory responses (Poncini et al., 2015). Galectin-3 (Gal-3)
and its specific ligands were over-expressed in splenic DCs after
infection by T. cruzi Tehuantepec strain, which lead to DC
increased adhesiveness and reduced migration (Vray et al., 2004).
Therefore, T. cruzi modulates Gal-3 and its ligands functionality
to improve infection, another immunomodulatory property of
T. cruzi (Vray et al., 2004). Another lectin-like receptor expressed
by immune system cells, Siglec-E (sialic acid-binding Ig-like
lectin-E), has also been implicated in T. cruzi infection. It is
well known that transference of sialic acid by T. cruzi trans-
sialidase (TS) from host cell to parasite surface mucin-like
molecules confers resistance to human complement, contributing
to infection (Tomlinson et al., 1994). In this context, pathogenic
T. cruzi Tulahuen strain (high TS activity) interacted more
to Siglec-E than non-pathogenic T. cruzi Tehuantepec strain
(reduced TS activity). This interaction led to an inhibitory effect
on DCs modulation, suppressing the production of cytokine
IL-12 and subsequent T-cell activation. In contrast, T. cruzi
Tehuantepec strain could not install an important parasitemia
(Erdmann et al., 2009). Together, those findings suggest that
T. cruzi (or parasite products) may lead to immunosuppression
through its interaction with DC lectin receptors (Terrazas et al.,
2010). Slamf1 (self-ligand adhesion molecule - CD150) is a co-
stimulatory molecule present in myeloid lineage and required
at the interface of antigen presenting cells and T cells (van
Driel et al., 2016). In vitro and in vivo experiments revealed
that Slamf1-deficient myeloid cells showed altered production of
cytokines and reduced parasite replication. For instance, much
lower IFN-γ production was detected in the heart of Slamf1
deficient mice than in the heart of WT mice. Additionally, Slamf1
deficient mice presented reduced cardiac damage despite of the
comparable number of infiltrating DCs, macrophages, CD4 and
CD8 T lymphocytes to that of WT animals. Therefore, T. cruzi
requires Slamf1 to replicate in DCs and its absence leads to less
production of myeloid cell specific factors by DCs, which are key
compounds to host immune response and infection outcomes
(Calderón et al., 2012).
Currently, there is an enormous amount of data that states a
direct association between mouse DC functional specializations
(antigen presentation or pathogen sensing) and their subsets.
However, after our meticulous review of literature in the field, it
is not unrealistic to conclude that the role of DC subsets in innate
immune response against T. cruzi needs to be more properly
addressed by researches since most cited works emphasize only
one surface phenotype as if all DCs are equally functional. The
same statement is valid for T. cruzi strains, a missing pattern
respect to DCs subsets and their level of activation and to T. cruzi
strains, which hampers an association concerning published data.
Table 1 summarizes the limited actual data in the murine DC-
T. cruzi system.
HUMAN DC−T. cruzi INTERACTION: IN
VITRO STUDIES
The first experiment that confirmed the ability of T. cruzi to
infect and reproduce inside a human DC was performed in 1999
(Van Overtvelt et al., 1999), a biological process that had already
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been known for Leishmania (Moll et al., 1995). The authors also
demonstrated that DCs, derived from monocytes and infected
with T. cruzi Tehuantepec strain, significantly reduced HLA-
DR and CD40 expression. In addition, these infected DCs
were neither IL-12 nor TNF-α producers (Van Overtvelt et al.,
1999). In a different study, using the same T. cruzi strain,
Van Overtvelt and co-workers showed that T. cruzi soluble
factor(s) released by the parasite itself into the DC culture
medium inhibits LPS induced MHC class I up-regulation on
the surface of human DC. Such inhibition may decrease the
protective effect of specific CD8+ T since infected DCs had
a weaker capacity of cross-presentation. This reduction of DC
function may influence the in vivo host’s ability to competently
combat T. cruzi infection (Van Overtvelt et al., 2002). It is well
known that a small family of type 1 glycoinositolphospholipids
(GIPLs) is abundant in T. cruzi cell surface and, therefore, such
molecules seem to have immunoregulatory activities (Brodskyn
et al., 2002; Medeiros et al., 2007). GIPLs isolated from T. cruzi
G (TcI) and Y (TcII) strains were incubated along with LPS
to stimulate DCs derived from monocytes. The results showed
that T. cruzi GIPL antigens direct the down-regulation of both
proinflammatory cytokines, such as TNF-α and IL-12 and anti-
inflammatory, such IL-10, in DCs. The parasite GIPL also
inhibited the expression of co-stimulatory molecules HLA-DR,
CD83, CD86, CD80, and CD40 on DC surface. Similar results
were achieved when the ceramide portion of GIPL molecule
alone was used to stimulate DC, suggesting that fragments from
the parasite glycoproteins could represent an evasion strategy
of T. cruzi. Altogether, GIPL seems to contribute to parasite
protection from the innate responses, allowing the beginning of
infection and also acts in an inhibitory way on DC maturation,
postponing an adequate immune response against T. cruzi
(Brodskyn et al., 2002). Otherwise, a parasite released protein
belonging to thiol-disulfide oxidoreductase family (Tc52) binds
to and induces human and murine DC maturation by TLR2
activation. DCs derived from monocytes treated with Tc52
showed higher expression of CD83, CD86, CD54 and HLA-
DR and an elevated production of IL-8, MCP-1, MIP-1α. These
in vitro data suggest that Tc52 may provide local recruitment
and activation of leukocyte and then DC migration to the lymph
node, where they can trigger B and T cell immune responses
(Ouaissi et al., 2002).
Yet, T. cruzi Tulahuen strain parasites enhance expression of
CD40 and CD80 on cord blood mDCs in a higher level compared
to mDCs from adult donors. CD8+ T cells proliferation was also
stimulated by those cord blood mDCs. In early life, immune
responses are considered of partial effectiveness, owing to the
relative immaturity of the human immune system therefore it
is possible that maternally transmitted IgGs might contribute to
overcome some deficiency of fetal/neonatal DCs and to protect
the fetus/newborn against pathogens that have already come
into contact with the mother (Rodriguez et al., 2012a). Another
study, performed by the same group, showed that T. cruzi can
induce maturation of this DC type without infecting them.
Rodriguez and coworkers found that blood cord and adult mDCs
that had contact with parasite but were not yet infected also
expressed high levels of CD80 and CD83. In addition, they
demonstrated that either infected mDCs or T. cruzi lysates
co-incubated mDCs have a similar expression pattern of their
surface molecules. The authors also showed that infection rate
in mDCs is lower than in monocytes and granulocytes, maybe
due to their enhanced capacity of phagocytosis when compared to
mature DCs (Rodriguez et al., 2012b). Consistent with the results
shown in murine model, modulation of DCs function varies
according to T. cruzi strain. In a comparative study, Magalhães
and colleagues demonstrated that T. cruzi Col cl1.7 (TcI) but
not Y (TcII) strain induces higher CD80 and CD86 expression,
while T. cruzi Y strain induces up-regulation of IL-10, TNF-α and
granzyme A production. Also, CD8+ T lymphocytes activated
by Col cl1.7 strain produced higher level of IL-17. Then, TcI
strain were capable of a higher monocyte activation, while the
profile induced by TcII was more inflammatory (Magalhães et al.,
2015). Figure 2 summarizes DC receptors referred to in this
review.
The present knowledge about the interaction between human
DCs and T. cruzi is restricted to in vitro models where expression
of some cytokines and surface molecules were analyzed, but
the specific functions of human DC subsets are only beginning
to be unraveled. Contradictory studies have been published
concerning DC–T. cruzi interactions, both in human and mouse
models. However it seems that T. cruzi virulent strains probably
take advantage of susceptible DCs to overcome host immune
response and successfully install the infection. Remarkably, those
modulated DCs will conduct a weak adaptive response with low
expression of MHC class I and II molecules and proinflammatory
cytokines, which are fundamental for controlling parasite
survival (Poncini et al., 2008, 2010; Alba Soto et al., 2010; da Costa
et al., 2014).
FUTURE: NEEDS AND EXPECTATIONS
Dendritic cells are crucial decision-making cells of the
immunological system as they direct tolerance, anergy,
and initiation/regulation of the adaptive immune responses
(Banchereau and Steinman, 1998). For these reasons, DC has
been proposed as targets for immunotherapy in diseases related
to autoimmunity and exacerbated immune responses, such as
autoimmune encephalomyelitis (Menges et al., 2002), thyroiditis
(Verginis et al., 2005), and arthritis (Jaen et al., 2009) or to
improve unsatisfactory immune responses toward tumor or
pathogens (Dubsky et al., 2005). Targeting these cells with
recombinant antibodies conjugated to autoantigens or pathogen
antigens could direct a less exacerbated response against certain
disease (Lutz, 2012).
ASP-2, an amastigote protein from T. cruzi Y strain, was
conjugated with αDEC205 antibody, DEC205 is a C-type lectin
endocytic receptor expressed in some DC populations and is
widely used for targeting DCs. Recombinant ASP-2/DEC205
antibody was injected in mice, resulting in higher IFN-γ
production by splenocytes and high proliferation of antigen-
specific CD4+ T cells (Rampazo et al., 2015). Thus, targeted
regulatory DCs could be used as an immunotherapy strategy
during disease undetermined form to prevent evolution to
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FIGURE 2 | Dendritic cell receptor–T. cruzi antigen interactions may induce host resistance or susceptibility to parasite by activating different DCs
signaling pathways. DCs maturation, cytokine production, and migration capacity could be up or down-regulated depending on the signaling pathways triggered
during the initial contact between DCs and the parasite. H: DC receptors already known to interact with parasite in human model. M: DC receptors already known to
interact with parasite in murine model. ?: May act as a maturation inducer or as regulatory cytokines activator.
the chronic phase. Nevertheless, host receptor and parasite
antigen should be carefully elected because they could influence
maturation signals received by DCs for orchestration of the
immune response (Cohn and Delamarre, 2014). Furthermore,
trypomastigote lysate -pulsed IL-10-deficient DC conferred
protection against T. cruzi infection to recipient mice by
secreting increased amounts of IFN-γ, enhancing antigen-
specific production and inducing endogenous DC activation.
This DC-based vaccination against T. cruzi also demonstrated
that IL-10 produced by sensitizing DC has a key role in inhibiting
the protection response (Alba Soto et al., 2010). DC-based
vaccine has also been successfully tested in Leishmania. Freshly
isolated pDC from mice pulsed with Leishmania antigen and
reinjected into host resulted in a protective effect, presenting
mixed Th1/Th2 response with secretion of IFN-γ, IL-4 and IL-10
(Remer et al., 2007).
Unfortunately, DC immunizations have an elevated cost,
which turns up this approach less attractive added to relative
efficiency of the current treatment for Chagas disease during
acute phase (Rassi et al., 2010; Cohn and Delamarre, 2014).
Nonetheless, this neglected disease remains with no vaccines
or antiparasitic drugs proven efficient in chronically infected
adults, when most patients are diagnosed. Thus, future DCs
immunization researches could be directed toward treatment for
the undetermined stage targeting tolerogenic DCs.
CONCLUSION
Although efforts have been devoted to deciphering DCs−T. cruzi
interaction, there is still much to be investigated before the
complete understanding of DC role in the induction of immunity
against T. cruzi. Moreover, our knowledge about that interaction
is mostly based on the regulation, differentiation and function
of the DC lineage from mouse. A challenge that needs to be
overcome is the difficulty in isolating subsets of DCs from human
tissue; only then we might be able to improve the understanding
of human DCs in a molecular level and perhaps develop vaccines
for the prevention or treatment of Chagas disease. Our review
reiterates that T. cruzi capacity to modulate host DCs is an
indispensable strategy to escape from innate immune response
with the purpose of its own survival. Nevertheless, DCs present
an efficient machinery to capture, process, and present antigens to
T cells and to activate B cells therefore their immunotherapeutic
potential may not be disregarded.
AUTHOR CONTRIBUTIONS
NG-J: participated in design and manuscript writing. FM:
participated in design and manuscript writing. CF: participated
in design and manuscript writing. IB: participated in design,
Frontiers in Microbiology | www.frontiersin.org 9 July 2016 | Volume 7 | Article 1076
fmicb-07-01076 July 12, 2016 Time: 16:16 # 10
Gil-Jaramillo et al. DC−T. cruzi Interaction in Chagas Disease
coordination, and manuscript writing. JS: participated in design,
coordination, and manuscript writing.
FUNDING
This study was funded by CNPq-Pronex-DF, FAPDF
(Grant number: 193.001.076/2015 and 193.000.822/2015),
and MCT/CNPq/FNDCT/FAPs/MEC/CAPES/PRO-CENTRO-
OESTE. NG-J received a scholarship from CAPES.
ACKNOWLEDGMENT
We thank Julian E. Palacio Hernández for image
editions.
REFERENCES
Abrahamsohn, I. A., and Coffman, R. L. (1996). Trypanosoma cruzi: IL-10, TNF,
IFN-gamma, and IL-12 regulate innate and acquired immunity to infection.
Exp. Parasitol. 84, 231–244. doi: 10.1006/expr.1996.0109
Alba Soto, C. D., Mirkin, G. A., Solana, M. E., and González Cappa, S. M.
(2003). Trypanosoma cruzi infection modulates in vivo expression of major
histocompatibility complex class II molecules on antigen-presenting cells and
T-cell stimulatory activity of dendritic cells in a strain-dependent manner.
Infect. Immun. 71, 1194–1199. doi: 10.1128/IAI.71.3.1194
Alba Soto, C. D., Solana, M. E., Poncini, C. V., Pino-Martinez, A. M., Tekiel, V.,
and González-Cappa, S. M. (2010). Dendritic cells devoid of IL-10 induce
protective immunity against the protozoan parasite Trypanosoma cruzi. Vaccine
28, 7407–7413. doi: 10.1016/j.vaccine.2010.08.105
Andrade, D. V., Gollob, K. J., and Dutra, W. O. (2014). Acute chagas disease: new
global challenges for an old neglected disease. PLoS Negl. Trop. Dis. 8:e3010.
doi: 10.1371/journal.pntd.0003010
Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of
immunity. Nature 392, 245–252. doi: 10.1038/32588
Bartholomeu, D. C., Ropert, C., Melo, M. B., Parroche, P., Junqueira, C. F., Teixeira,
S. M. R., et al. (2008). Recruitment and endo-lysosomal activation of TLR9 in
dendritic cells infected with Trypanosoma cruzi. J. Immunol. 181, 1333–1344.
doi: 10.4049/jimmunol.181.2.1333
Bastos, C. J. C., Aras, R., Mota, G., Reis, F., Dias, J. P., de Jesus, R. S., et al. (2010).
Clinical outcomes of thirteen patients with acute chagas disease acquired
through oral transmission from two urban outbreaks in Northeastern Brazil.
PLoS Negl. Trop. Dis. 4:e711. doi: 10.1371/journal.pntd.0000711
Batalla, E. I., Pino Martínez, A. M., Poncini, C. V., Duffy, T., Schijman, A. G.,
González Cappa, S. M., et al. (2013). Impairment in natural killer cells editing
of immature dendritic cells by infection with a virulent Trypanosoma cruzi
population. J. Innate Immun. 5, 494–504. doi: 10.1159/000350242
Bermudez, J., Davies, C., Simonazzi, A., Real, J. P., and Palma, S. (2015). Current
drug therapy and pharmaceutical challenges for Chagas disease. Acta Trop. 156,
1–16. doi: 10.1016/j.actatropica.2015.12.017
Bern, C. (2011). Antitrypanosomal therapy for chronic Chagas’ disease. N. Engl. J.
Med. 364, 2527–2534. doi: 10.1056/NEJMct1014204
Bern, C. (2015). Chagas’ Disease. N. Engl. J. Med. 373, 456–466. doi:
10.1056/NEJMra1410150
Blum, J. S., Wearsch, P. A., and Cresswell, P. (2013). Pathways of antigen
processing. Annu. Rev. Immunol. 31, 443–473. doi: 10.1146/annurev-immunol-
032712-095910
Borges, D. C., Araújo, N. M., Cardoso, C. R., and Lazo Chica, J. E. (2012).
Different parasite inocula determine the modulation of the immune response
and outcome of experimental Trypanosoma cruzi infection. Immunology 138,
145–156. doi: 10.1111/imm.12022
Boussiotis, V. A., Freeman, G. J., Gribben, J., and Nadler, L. (1996). The role of
B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of
productive immunity and down-regulation of the immune response. Immunol.
Rev. 153, 5–26. doi: 10.1111/j.1600-065X.1996.tb00918.x
Brodskyn, C., Patricio, J., Oliveira, R., Lobo, L., Arnholdt, A., Mendonça-
previato, L., et al. (2002). Glycoinositolphospholipids from Trypanosoma cruzi
interfere with macrophages and dendritic cell responses. Infect. Immun. 70,
3736–3743. doi: 10.1128/IAI.70.7.3736-3743.2002
Caetano, B. C., Carmo, B. B., Melo, M. B., Cerny, A., dos Santos, S. L., Bartholomeu,
D. C., et al. (2011). Requirement of UNC93B1 reveals a critical role for Toll-
Like Receptor 7 in host resistance to primary infection with Trypanosoma cruzi.
J. Immunol. 187, 1903–1911. doi: 10.4049/jimmunol.1003911
Calderón, J., Maganto-Garcia, E., Punzón, C., Carrión, J., Terhorst, C., and
Fresno, M. (2012). The receptor Slamf1 on the surface of myeloid lineage
cells controls susceptibility to infection by Trypanosoma cruzi. PLoS Pathog.
8:e1002799. doi: 10.1371/journal.ppat.1002799
Camargo, R., Faria, L. O., Kloss, A., Favali, C. B. F., Kuckelkorn, U., Kloetzel,
P. M., et al. (2014). Trypanosoma cruzi infection down-modulates the
immunoproteasome biosynthesis and the MHC class I cell surface expression
in HeLa cells. PLoS ONE 9:e95977. doi: 10.1371/journal.pone.0095977
Campos, M. A., Closel, M., Valente, E. P., Cardoso, J. E., Akira, S., Alvarez-
leite, J. I., et al. (2004). Impaired production os proinflammatory cytokines
and host resistance to acute infection with Trypanosoma cruzi in mice lacking
functional myeliod differentation factor 88. J. Immunol. 172, 1711–1718. doi:
10.4049/jimmunol.172.3.1711
Cardoso, M. S., Reis-cunha, J. L., Bartholomeu, D. C., Fernandez, M. M.,
and Bartholomeu, D. C. (2016). Evasion of the Immune Response by
Trypanosoma cruzi during Acute Infection. Front. Immunol. 6:659. doi:
10.3389/fimmu.2015.00659
Chaussabel, D., Pajak, B., Vercruysse, V., Bisseyé, C., Garzé, V., Habib, M., et al.
(2003). Alteration of migration and maturation of dendritic cells and T-Cell
depletion in the course of experimental Trypanosoma cruzi infection. Lab.
Investig. 83, 1373–1382. doi: 10.1097/01.LAB.0000087587.93781.6F
Cohn, L., and Delamarre, L. (2014). Dendritic cell-targeted vaccines. Front.
Immunol. 5:255. doi: 10.3389/fimmu.2014.00255
Collin, M., Mcgovern, N., and Haniffa, M. (2013). Human dendritic cell subsets.
Immunology 140, 22–30. doi: 10.1111/imm.12117
Cooke, G., Armstrong, M. E., and Donnelly, S. C. (2009). Macrophage migration
inhibitory factor (MIF), enzymatic activity and the inflammatory response.
Biofactors 35, 165–168. doi: 10.1002/biof.27
Corinti, S., Albanesi, C., la Sala, A., Pastore, S., and Girolomoni, G. (2001).
Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol.
166, 4312–4318. doi: 10.4049/jimmunol.166.7.4312
Coura, J. R., Dias, J. C. P., Frasch, A. C. C., Guhl, F., Lazzari, J. O., Lorca, M.,
et al. (2002). Control of Chagas disease. Adv. Parasitol. 61, 129–165. doi:
10.1016/S0065-308X(05)61004-4.
da Costa, T. A., Silva, M. V., Mendes, M. T., Carvalho-Costa, T. M., Batista, L. R.,
Lages-Silva, E., et al. (2014). Immunomodulation byTrypanosoma cruzi: toward
understanding the association of dendritic cells with infecting TcI and TcII
populations. J. Immunol. Res. 2014, 1–12. doi: 10.1155/2014/962047
D’Avila-Levy, C. M., Boucinha, C., Kostygov, A., Santos, H. L. C., Morelli, K. A.,
Grybchuk-Ieremenko, A., et al. (2015). Exploring the environmental diversity
of kinetoplastid flagellates in the high-throughput DNA sequencing era. Mem.
Inst. Oswaldo Cruz 110, 956–965. doi: 10.1590/0074-02760150253
de Lana, M., Marques, E., and Machado, D. M. (2010). Biology of “Trypanosoma
cruzi” and Biological Diversity, 1st Edn. Amsterdam: Elsevier Inc.
Deane, M. P., Lenzi, H. L., and Jansen, A. (1984). Trypanosoma cruzi: vertebrate
and invertebrate cycles in the same mammal host, the opossum Didelphis
marsupialis. Mem. Inst. Oswaldo Cruz 79, 513–515. doi: 10.1590/S0074-
02761984000400021
Demangel, C., Bertolino, P., and Britton, W. J. (2002). Autocrine IL-10
impairs dendritic cell (DC)-derived immune responses to mycobacterial
infection by suppressing DC trafficking to draining lymph nodes and
local IL-12 production. Eur. J. Immunol. 32, 994–1002. doi: 10.1002/1521-
4141(200204)32:4<994::AID-IMMU994>3.3.CO;2-Y
den Haan, J. M. M., Arens, R., and van Zelm, M. C. (2014). The activation
of the adaptive immune system: cross-talk between antigen-presenting cells,
T cells and B cells. Immunol. Lett. 162, 103–112. doi: 10.1016/j.imlet.2014.
10.011
Frontiers in Microbiology | www.frontiersin.org 10 July 2016 | Volume 7 | Article 1076
fmicb-07-01076 July 12, 2016 Time: 16:16 # 11
Gil-Jaramillo et al. DC−T. cruzi Interaction in Chagas Disease
Dubsky, P., Ueno, H., Piqueras, B., Connolly, J., Banchereau, J., and Palucka, A. K.
(2005). Human dendritic cell subsets for vaccination. J. Clin. Immunol. 25,
551–572. doi: 10.1007/s10875-005-8216-7
Dutra, W. O., Menezes, C. A. S., Magalhães, L. M. D., and Gollob, K. J. (2015).
Immunoregulatory networks in human Chagas disease. Parasite Immunol. 36,
377–387. doi: 10.1111/pim.12107
Erdmann, H., Steeg, C., Koch-nolte, F., Fleischer, B., and Jacobs, T. (2009).
Sialylated ligands on pathogenic Trypanosoma cruzi interact with Siglec-
E (sialic acid-binding Ig-like lectin-E). Cell. Microbiol. 11, 1600–1611. doi:
10.1111/j.1462-5822.2009.01350.x
Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., and
Trinchieri, G. (2002). Reciprocal activating interaction between natural killer
cells and dendritic cells. J. Exp. Med. 195, 327–333. doi: 10.1084/jem.20010938
Gravina, H. D., Antonelli, L., Gazzinelli, R. T., and Ropert, C. (2013).
Differential Use of TLR2 and TLR9 in the regulation of immune responses
during the infection with Trypanosoma cruzi. PLoS ONE 8:e63100. doi:
10.1371/journal.pone.0063100
Haniffa, M., Ginhoux, F., Wang, X.-N., Bigley, V., Abel, M., Dimmick, I., et al.
(2009). Differential rates of replacement of human dermal dendritic cells and
macrophages during hematopoietic stem cell transplantation. J. Exp. Med. 206,
371–385. doi: 10.1084/jem.20081633
Holdsworth, S. R., and Can, P. Y. (2015). Cytokines: names and numbers
you should care about. Clin. J. Am. Soc. Nephrol. 10, 2243–2254. doi:
10.2215/CJN.07590714
Hotez, P. J., Molyneux, D. H., Fenwick, A., Kumaresan, J., Sachs, S. E., Sachs,
J. D., et al. (2007). Control of neglected tropical diseases. N. Engl. J. Med. 357,
1018–1027. doi: 10.1056/NEJMra064142
Jaen, O., Rullé, S., Bessis, N., Zago, A., Boissier, M. C., and Falgarone, G. (2009).
Dendritic cells modulated by innate immunity improve collagen-induced
arthritis and induce regulatory T cells in vivo. Immunology 126, 35–44. doi:
10.1111/j.1365-2567.2008.02875.x
Klos, A., Tenner, A. J., Johswich, K. O., Ager, R. R., Reis, E. S., and Köhl, J.
(2009). The role of the anaphylatoxins in health and disease. Mol. Immunol.
46, 2753–2766. doi: 10.1016/j.molimm.2009.04.027
Koga, R., Hamano, S., Kuwata, H., Atarashi, K., Ogawa, M., Hisaeda, H.,
et al. (2006). TLR-dependent induction of IFN- β mediates host
defense against Trypanosoma cruzi. J. Immunol. 177, 7059–7066. doi:
10.4049/jimmunol.177.10.7059
Kropf, S. P., and Sá, M. R. (2009). The discovery of Trypanosoma cruzi and Chagas
disease (1908-1909): tropical medicine in Brazil.Hist. Cienc. SaudeManguinhos.
16(Suppl. 1), 13–34. doi: 10.1590/S0104-59702009000500002
Laucella, S. A., Rottenberg, M. E., and de Titto, E. H. (1996). Role of cytokines
in resistance and pathology in Trypanosoma cruzi infection. Rev. Argent
Microbiol. 28, 99–109.
Lewis, K. L., and Reizis, B. (2012). Dendritic cells: arbiters of immunity and
immunological tolerance. Cold Spring Harb. Perspect. Biol. 4:a007401. doi:
10.1101/cshperspect.a007401
Lipscomb, M. F., and Masten, B. J. (2002). Dendritic cells: immune regulators in
health and disease. Physiol. Rev. 82, 97–130. doi: 10.1152/physrev.00023.2001
Lutz, M. B. (2012). Therapeutic potential of semi-mature dendritic cells for
tolerance induction. Front. Immunol. 3:123. doi: 10.3389/fimmu.2012.00123
Machado, F. S., Dutra, W. O., Esper, L., Gollob, K., Teixeira, M., Factor, S. M., et al.
(2013). Current understanding of immunity to Trypanosoma cruzi infection
and pathogenesis os Chagas disease. Semin. Immunopathol. 34, 753–770. doi:
10.1007/s00281-012-0351-7
Magalhães, L. M. D., Viana, A., Chiari, E., Galvão, L. M. C., Gollob, K. J., and Dutra,
W. O. (2015). Differential activation of human monocytes and lymphocytes by
distinct strains of Trypanosoma cruzi. PLoS Negl. Trop. Dis. 9:e0003816. doi:
10.1371/journal.pntd.0003816
Manchola, N. C., Rapado, L. N., Barison, M. J., and Silber, A. M. (2015).
Biochemical characterization of branched chain amino acids uptake in
Trypanosoma cruzi. J. Eukaryot. Microbiol. 63, 299–308. doi: 10.1111/jeu.12278
Medeiros, M. M., Peixoto, J. R., Oliveira, A.-C., Cardilo-Reis, L., Koatz,
V. L. G., Van Kaer, L., et al. (2007). Toll-like receptor 4 (TLR4)-
dependent proinflammatory and immunomodulatory properties of the
glycoinositolphospholipid (GIPL) from Trypanosoma cruzi. J. Leukoc. Biol. 82,
488–496. doi: 10.1189/jlb.0706478
Menges, M., RöBner, S., Voigtländer, C., Schindler, H., Kukutsch, N. A., Bogdan, C.,
et al. (2002). Repetitive injections of dendritic cells matured with tumor necrosis
factor alpha induce antigen-specific protection of mice from autoimmunity.
J. Exp. Med. 195, 15–21. doi: 10.1084/jem.20011341
Moll, H., Flohé, S., and Röllinghoff, M. (1995). Dendritic cells in Leishmaniamajor-
immune mice harbor persistent parasites and mediate an antigen-specific T cell
immune response. Eur. J. Immunol. 25, 693–699. doi: 10.1002/eji.1830250310
Monteiro, A. C., Schmitz, V., Morrot, A., de Arruda, L. B., Nagajyothi, F.,
Granato, A., et al. (2007). Bradykinin B 2 receptors of dendritic cells, acting
as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical
for the development of protective Type-1 responses. PLOS Pathog. 3:e185. doi:
10.1371/journal.ppat.0030185
Monteiro, A. C., Schmitz, V., Svensjo, E., Gazzinelli, R. T., Almeida, I. C.,
Todorov, A., et al. (2006). Cooperative activation of TLR2 and bradykinin B2
receptor is required for induction of type 1 immunity in a mouse model of
subcutaneous infection byTrypanosoma cruzi. J. Immunol. 177, 6325–6335. doi:
10.4049/jimmunol.177.9.6325
Muñoz-Saravia, S. G., Haberland, A., Wallukat, G., and Schimke, I. (2012). Chronic
Chagas’ heart disease: a disease on its way to becoming a worldwide health
problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory
medicine. Heart Fail. Rev. 17, 45–64. doi: 10.1007/s10741-010-9211-5
Nardy, A. F., Freire-de-Lima, C. G., and Morrot, A. (2015). Immune
evasion strategies of Trypanosoma cruzi. J. Immunol. Res. 2015:7. doi:
10.1155/2015/178947
Neefjes, J., Jongsma, M. L., Paul, P., and Bakke, O. (2011). Towards a systems
understanding of MHC class I and MHC class II antigen presentation. Nat. Rev.
Immunol. 11, 823–836. doi: 10.1038/nri3084
Nóbrega, A. A., Garcia, M. H., Tatto, E., Obara, M. T., Costa, E., Sobel, J., et al.
(2009). Oral transmission of chagas disease by consumption of Açaí palm fruit,
Brazil. Emerg. Infect. Dis. 15, 653–655. doi: 10.3201/eid1504.081450
Oliveira, A., Alencar, B. C., De Tzelepis, F., Klezewsky, W., Raquel, N., Neves, F. S.,
et al. (2010). Impaired innate immunity in Tlr4 2 / 2 mice but preserved CD8+
T cell responses against Trypanosoma cruzi in Tlr4-, Tlr2-, Tlr9- or myd88-
deficient mice. PLoS Pathog. 6:e1000870. doi: 10.1371/journal.ppat.1000870
O’Neill, D. W., Adams, S., and Bhardwaj, N. (2004). Manipulating dendritic cell
biology for the active immunotherapy of cancer. Blood J. 104, 2235–2246. doi:
10.1182/blood-2003-12-4392
Ouaissi, A., Guilvard, E., Delneste, Y., Caron, G., Magistrelli, G., Herbault, N.,
et al. (2002). The Trypanosoma cruzi Tc52-released protein induces human
dendritic cell maturation, signals via toll-like receptor 2, and confers
protection against lethal infection. J. Immunol. 168, 6366–6374. doi:
10.4049/jimmunol.168.12.6366
Pearce, E. J., and Everts, B. (2015). Dendritic cell metabolism. Nat. Rev. Immunol.
15, 18–29. doi: 10.1038/nri3771
Piccioli, D., Sbrana, S., Melandri, E., and Valiante, N. M. (2002). Contact-
dependent stimulation and inhibition of dendritic cells by natural killer cells.
J. Exp. Med. 195, 335–341. doi: 10.1084/jem.20010934
Planelles, L., Thomas, M. C., Marañón, C., Morell, M., and López, M. C. (2003).
Differential CD86 and CD40 co-stimulatory molecules and cytokine expression
pattern induced by Trypanosoma cruzi in APCs from resistant or susceptible
mice. Clin. Exp. Immunol. 131, 41–47. doi: 10.1046/j.1365-2249.2003.02022.x
Poncini, C. V., Giménez, G., Pontillo, C. A., Alba-Soto, C. D., de Isola,
E. L. D., Piazzón, I., et al. (2010). Central role of extracellular signal-regulated
kinase and Toll-like receptor 4 in IL-10 production in regulatory dendritic
cells induced by Trypanosoma cruzi. Mol. Immunol. 47, 1981–1988. doi:
10.1016/j.molimm.2010.04.016
Poncini, C. V., Ilarregui, J. M., Batalla, E. I., Engels, S., Cerliani, J. P., Cucher,
M. A., et al. (2015). Trypanosoma cruzi infection imparts a regulatory program
in dendritic cells and T cells via galectin-1–dependent mechanisms. J. Immunol.
195, 3311–3324. doi: 10.4049/jimmunol.1403019
Poncini, C. V., Soto, C. D. A., Batalla, E., Solana, M. E., and Gonzalez Cappa, S. M.
(2008). Trypanosoma cruzi induces regulatory dendritic cells in vitro. Infect.
Immun. 76, 2633–2641. doi: 10.1128/IAI.01298-07
Ramírez, J. D., Guhl, F., Rendón, L. M., Rosas, F., Marin-Neto, J. A., and Morillo,
C. A. (2010). Chagas cardiomyopathy manifestations and Trypanosoma cruzi
genotypes circulating in chronic chagasic patients. PLoS Negl. Trop. Dis. 4:e899.
doi: 10.1371/journal.pntd.0000899
Frontiers in Microbiology | www.frontiersin.org 11 July 2016 | Volume 7 | Article 1076
fmicb-07-01076 July 12, 2016 Time: 16:16 # 12
Gil-Jaramillo et al. DC−T. cruzi Interaction in Chagas Disease
Rampazo, E. V., Amorim, K. N. S., and Yamamoto, M. M. (2015). Antigen targeting
to dendritic cells allows the identification of a CD4 T-Cell epitope within an
immunodominant Trypanosoma cruzi antigen. PLoS ONE 10:e0117778. doi:
10.1371/journal.pone.0117778
Rassi, A., Rassi, A., and Marin-Neto, J. A. (2010). Chagas disease. Lancet 375,
1388–1402. doi: 10.1016/S0140-6736(10)60061-X
Remer, K. A., Apetrei, C., Schwarz, T., Linden, C., and Moll, H. (2007).
Vaccination with plasmacytoid dendritic cells induces protection against
infection with Leishmania major in mice. Eur. J. Immunol. 37, 2463–2473. doi:
10.1002/eji.200636780
Rodriguez, P., Carlier, Y., and Truyens, C. (2012a). Activation of cord blood
myeloid dendritic cells by Trypanosoma cruzi and parasite-specific antibodies,
proliferation of CD8+ T cells, and production of IFN-gamma. Med. Microbiol.
Immunol. 201, 157–169. doi: 10.1007/s00430-011-0217-y
Rodriguez, P., Carlier, Y., and Truyens, C. (2012b). Trypanosoma cruzi
activates cord blood myeloid dendritic cells independently of cell
infection. Med. Microbiol. Immunol. 201, 287–296. doi: 10.1007/s00430-012-
0230-9
Romano, P. S., Cueto, J. A., Casassa, A. F., Vanrell, M. C., Gottlieb, R. A.,
and Colombo, M. I. (2012). Molecular and cellular mechanisms involved
in the Trypanosoma cruzi/host cell interplay. IUBMB Life 64, 387–396. doi:
10.1002/iub.1019
Schmitz, V., Almeida, L. N., Svensjö, E., Monteiro, A. C., Köhl, J., and Scharfstein, J.
(2014). C5a and bradykinin receptor cross-talk regulates innate and adaptive
immunity in Trypanosoma cruzi infection. J. Immunol. 193, 3613–3623. doi:
10.4049/jimmunol.1302417
Schmunis, G. A. (2007). Epidemiology of Chagas disease in non-endemic
countries: the role of international migration. Mem. Inst. Oswaldo Cruz 102,
75–85. doi: 10.1590/S0074-02762007005000093
Segura, E. (2016). “Review of mouse and human dendritic cell subsets,” in
Dendritic Cell Protocols, eds E. Segura and N. Onai (New York, NY: Springer
Science+Business Media), 3–15. doi: 10.1007/978-1-4939-3606-9_1
Segura, E., and Amigorena, S. (2015). Cross-Presentation in Mouse and Human
Dendritic Cells, 1st Edn. Amsterdam: Elsevier Inc.
Stecconi-Silva, R. B., Andreoli, W. K., and Mortara, R. A. (2003). Parameters
affecting cellular invasion and escape from the parasitophorous vacuole by
different infective forms of Trypanosoma cruzi. Mem. Inst. Oswaldo Cruz 98,
953–958. doi: 10.1590/S0074-02762003000700016
Steinman, R. M. (2007). Dendritic cells: versatile controllers of the immune system.
Nat. Med. 13, 1155–1159. doi: 10.1038/nm1643
Stevens, J. R. (2008). Kinetoplastid phylogenetics, with special reference
to the evolution of parasitic trypanosomes. Parasite 15, 226–232. doi:
10.1051/parasite/2008153226
Steverding, D. (2014). The history of chagas disease. Parasit Vectors 7, 1–8. doi:
10.1186/1756-3305-7-317
Strasen, J., Williams, T., Ertl, G., Zoller, T., Stich, A., and Ritter, O. (2013).
Epidemiology of chagas disease in Europe: many calculations, little knowledge.
Clin. Res. Cardiol. 103, 1–10. doi: 10.1007/s00392-013-0613-y
Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflammation.
Cell 140, 805–820. doi: 10.1016/j.cell.2010.01.022
Teixeira, A., Vinaud, M., and Castro, A. M. (2009). Emerging Chagas Disease.
Brasília: Bentham.
Terrazas, C. A., Huitron, E., Vazquez, A., Juarez, I., Camacho, G. M., Calleja,
E. A., et al. (2011). MIF synergizes with Trypanosoma cruzi antigens to promote
efficient dendritic cell maturation and IL-12 production via p38 MAPK. Int. J.
Biol. Sci. 7, 1298–1310. doi: 10.7150/ijbs.7.1298
Terrazas, C. A., Terrazas, L. I., and Gómez-García, L. (2010). Modulation of
dendritic cell responses by parasites: a common strategy to survive. J. Biomed.
Biotechnol. 2010:357106. doi: 10.1155/2010/357106
Tibayrenc, M. (1998). Genetic epidemiology of parasitic protozoa and other
infectious agents: the need for an integrated approach. Int. J. Parasitol. 28,
85–104. doi: 10.1016/S0020-7519(97)00180-X
Tomlinson, S., Pontes de Carvalho, L. C., Vandekerckhove, F., and Nussenzweig, V.
(1994). Role of sialic acid in the resistance of Trypanosoma cruzi
trypomastigotes to complement. J. Immunol. 153, 3141–3147.
Tonelli, R. R., Silber, A. M., Almeida-de-Faria, M., Hirata, I. Y., Colli, W., and
Alves, J. M. (2004). L-proline is essential for the intracellular differentiation
of Trypanosoma cruzi. Cell. Microbiol. 6, 733–741. doi: 10.1111/j.1462-
5822.2004.00397.x
van Driel, B. J., Liao, G., Engel, P., and Terhorst, C. (2016). Responses
to microbial challenges by SLAMF receptors. Front. Immunol. 7:4. doi:
10.3389/fimmu.2016.00004
Van Overtvelt, L., Andrieu, M., Verhasselt, V., Connan, F., Choppin, J.,
Vercruysse, V., et al. (2002). Trypanosoma cruzi down-regulates
lipopolysaccharide-induced MHC class I on human dendritic cells and
impairs antigen presentation to specific CD8 + T lymphocytes. Int. Immunol.
14, 1135–1144. doi: 10.1093/intimm/dxf077
Van Overtvelt, L., Vanderheyde, N., Verhasselt, V., Ismaili, J., De Vos, L.,
Goldman, M., et al. (1999). Trypanosoma cruzi infects human dendritic
cells and prevents their maturation: inhibition of cytokines, HLA-DR, and
costimulatory molecules. Infect. Immun. 67, 4033–4040.
Vasta, G. R. (2009). Roles of galectins in infection. Nat. Rev. Microbiol. 7, 424–438.
doi: 10.1038/nrmicro2146
Verginis, P., Li, H. S., and Carayanniotis, G. (2005). Tolerogenic semimature
dendritic cells suppress experimental autoimmune thyroiditis by activation of
thyroglobulin-specific CD4+CD25+ T cells. J. Immunol. 174, 7433–7439. doi:
10.4049/jimmunol.174.11.7433
Verhasselt, V., Buelens, C., Willems, F., De Groote, D., Haeffner-Cavaillon, N., and
Goldman, M. (1997). Bacterial lipopolysaccharide stimulates the production of
cytokines and the expression of costimulatory molecules by human peripheral
blood dendritic cells: evidence for a soluble CD14-dependent pathway.
J. Immunol. 158, 2919–2925.
Vray, B., Camby, I., Vercruysse, V., Mijatovic, T., Bovin, N. V., Ricciardi-
Castagnoli, P., et al. (2004). Up-regulation of galectin-3 and its ligands by
Trypanosoma cruzi infection with modulation of adhesion and migration of
murine dendritic cells. Glycobiology 14, 647–657. doi: 10.1093/glycob/cwh068
Vyas, J. M., Van der Veen, A. G., and Ploegh, H. L. (2008). The known unknowns
of antigen processing and presentation. Nat. Rev. Immunol. 8, 607–618. doi:
10.1038/nri2368
Watanabe Costa, R., da Silveira, J. F., and Bahia, D. (2016). Interactions between
Trypanosoma cruzi secreted proteins and host cell signaling pathways. Front.
Microbiol. 7:388. doi: 10.3389/fmicb.2016.00388
Wilkinson, S. R., Bot, C., Kelly, J. M., and Hall, B. S. (2011). Trypanocidal activity of
nitroaromatic prodrugs: current treatments and future perspectives. Curr. Top.
Med. Chem. 11, 2072–2084. doi: 10.2174/156802611796575894
World Health Organization (2015). World Health Organization: Chagas Disease.
Available at: http://www.who.int/mediacentre/factsheets/fs340/en/
Yoshida, N. (2006). Molecular basis of mammalian cell invasion
by Trypanosoma cruzi. An. Acad. Bras. Cienc. 78, 87–111. doi:
10.1590/S0001-37652006000100010
Zingales, B., Andrade, S. G., Briones, M. R. S., Campbell, D. A., Chiari, E.,
Fernandes, O., et al. (2009). A new consensus for Trypanosoma cruzi
intraspecific nomenclature: second revision meeting recommends TcI to
TcVI. Mem. Inst. Oswaldo Cruz 104, 1051–1054. doi: 10.1590/S0074-
02762009000700021
Zingales, B., Miles, M. A., Campbell, D. A., Tibayrenc, M., Macedo, A. M.,
Teixeira, M. M. G., et al. (2012). The revised Trypanosoma cruzi subspecific
nomenclature: rationale, epidemiological relevance and research applications.
Infect. Genet. Evol. 12, 240–253. doi: 10.1016/j.meegid.2011.12.009
Zúñiga, E., Gruppi, A., Hirabayashi, J., Kasai, K. I., and Rabinovich, G. A. (2001a).
Regulated expression and effect of galectin-1 on Trypanosoma cruzi-infected
macrophages: modulation of microbicidal activity and survival. Infect. Immun.
69, 6804–6812. doi: 10.1128/IAI.69.11.6804-6812.2001
Zúñiga, E., Rabinovich, G. A., Iglesias, M. M., and Gruppi, A. (2001b). Regulated
expression of galectin-1 during B-cell activation and implications for T-cell
apoptosis. J. Leukoc. Biol. 70, 73–79.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Gil-Jaramillo, Motta, Favali, Bastos and Santana. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Microbiology | www.frontiersin.org 12 July 2016 | Volume 7 | Article 1076
